Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback